{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:59:33Z","timestamp":1789340373263,"version":"build-2803163510"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T00:00:00Z","timestamp":1392336000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0088497","type":"journal-article","created":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T22:01:14Z","timestamp":1392415274000},"page":"e88497","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic Drug Monitoring and Pharmacogenetic Study of HIV-Infected Ethnic Chinese Receiving Efavirenz-Containing Antiretroviral Therapy with or without Rifampicin-Based Anti-Tuberculous Therapy"],"prefix":"10.1371","volume":"9","author":[{"given":"Kuan-Yeh","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hua","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Song","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Ru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue-Yo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,2,14]]},"reference":[{"key":"ref1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2013) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf\" xlink:type=\"simple\">http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf<\/ext-link>. Accessed: 16 June 2013."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"C Marzolini","year":"2001","journal-title":"AIDS"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"D Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/AAC.47.1.130-137.2003","article-title":"Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398","volume":"47","author":"M Pfister","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication","volume":"13","author":"W Stohr","year":"2008","journal-title":"Antivir Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/jac\/dkr360","article-title":"Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals","volume":"66","author":"J Poeta","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.00899-08","article-title":"CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India","volume":"53","author":"G Ramachandran","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"DW Haas","year":"2004","journal-title":"AIDS"},{"key":"ref9","unstructured":"Food and Drug Administration. Sustiva labeling update\/dosing adjustment with rifampin. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm294476.htm\" xlink:type=\"simple\">http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm294476.htm<\/ext-link>. Accessed: 16 June 2013."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/cit246","article-title":"Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study","volume":"57","author":"AF Luetkemeyer","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref11","unstructured":"Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers [abstract 42280]; 1998 June 28-July 3; Geneva, Switzerland."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis","volume":"41","author":"LF Lopez-Cortes","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","article-title":"High prevalence of the CYP2B6 516G\u2013&gt;T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe","volume":"64","author":"C Nyakutira","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-6405-7-8","article-title":"Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV\/TB co-infected Thai adults","volume":"7","author":"S Uttayamakul","year":"2010","journal-title":"AIDS Res Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejps.2006.04.004","article-title":"Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese","volume":"29","author":"S Guan","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchromb.2006.03.014","article-title":"Simple and rapid liquid chromatography method for determination of efavirenz in plasma","volume":"835","author":"G Ramachandran","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","article-title":"Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G&gt;T polymorphism on efavirenz concentrations in adults in South Africa","volume":"14","author":"K Cohen","year":"2009","journal-title":"Antivir Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/QAD.0b013e3283427e05","article-title":"Paradoxically elevated efavirenz concentrations in HIV\/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy","volume":"25","author":"A Kwara","year":"2011","journal-title":"AIDS"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"M Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":"Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens","volume":"66","author":"C Wyen","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1124\/dmd.104.001107","article-title":"Haplotype structure and allele frequencies of CYP2B6 in a Korean population","volume":"32","author":"JY Cho","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00228-002-0499-5","article-title":"Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population","volume":"58","author":"M Hiratsuka","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and\/or Nelfinavir: an Adult Aids Clinical Trials Group Study","volume":"192","author":"DW Haas","year":"2005","journal-title":"J Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1177\/0091270008321790","article-title":"Pharmacokinetics of efavirenz when co-administered with rifampin in TB\/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation","volume":"48","author":"A Kwara","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1086\/522175","article-title":"Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26","volume":"45","author":"H Gatanaga","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1128\/AAC.00492-09","article-title":"Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin","volume":"53","author":"W Manosuthi","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3851\/IMP2483","article-title":"Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg","volume":"18","author":"L Borand","year":"2013","journal-title":"Antivir Ther"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0088497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:46:00Z","timestamp":1688996760000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0088497"}},"subtitle":[],"editor":[{"given":"Pierre","family":"Roques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,14]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0088497","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,14]]}}}